Join Growin Stock Community!

Moderna, inc.MRNA.US Overview

US StockHealthcare
(No presentation for MRNA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MRNA AI Insights

MRNA Overall Performance

MRNA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MRNA Recent Performance

-2.45%

Moderna, inc.

0.05%

Avg of Sector

-0.31%

S&P500

MRNA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MRNA Key Information

MRNA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MRNA Profile

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Price of MRNA

MRNA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MRNA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-7.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.77
PB Ratio
2.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
55.35%
Net Margin
-145.16%
Revenue Growth (YoY)
-39.93%
Profit Growth (YoY)
-39.28%
3-Year Revenue Growth
-48.91%
3-Year Profit Growth
-58.52%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-7.22
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.77
PB Ratio
2.34
Price-to-FCF
-
Gross Margin
55.35%
Net Margin
-145.16%
Revenue Growth (YoY)
-39.93%
Profit Growth (YoY)
-39.28%
3-Year Revenue Growth
-48.91%
3-Year Profit Growth
-58.52%

  • When is MRNA's latest earnings report released?

    The most recent financial report for Moderna, inc. (MRNA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MRNA's short-term business performance and financial health. For the latest updates on MRNA's earnings releases, visit this page regularly.

  • What is the operating profit of MRNA?

    According to the latest financial report, Moderna, inc. (MRNA) reported an Operating Profit of -857M with an Operating Margin of -126.4% this period, representing a growth of 31.22% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MRNA's revenue growth?

    In the latest financial report, Moderna, inc. (MRNA) announced revenue of 678M, with a Year-Over-Year growth rate of -29.81%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does MRNA have?

    At the end of the period, Moderna, inc. (MRNA) held Total Cash and Cash Equivalents of 2.6B, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MRNA go with three margins increasing?

    In the latest report, Moderna, inc. (MRNA) did not achieve the “three margins increasing” benchmark, with a gross margin of 33.3%%, operating margin of -126.4%%, and net margin of -121.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MRNA's profit trajectory and future growth potential.

  • Is MRNA's EPS continuing to grow?

    According to the past four quarterly reports, Moderna, inc. (MRNA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -2.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MRNA?

    Moderna, inc. (MRNA)'s Free Cash Flow (FCF) for the period is 891M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 194.06% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MRNA?

    The latest valuation data shows Moderna, inc. (MRNA) has a Price-To-Earnings (PE) ratio of -6.98 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.